دورية أكاديمية

Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis.

التفاصيل البيبلوغرافية
العنوان: Precision medicine: Externally validated explainable AI support tool for predicting sustainability of infliximab and vedolizumab in ulcerative colitis.
المؤلفون: Konikoff T; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Loebl N; Rabin Medical Center Innovation Lab, Rabin Medical Center, Petah Tikva, Israel., Yanai H; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Libchik D; Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel., Kopylov U; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Division of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Albshesh A; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; Division of Gastroenterology, Sheba Medical Center, Ramat Gan, Israel., Weisshof R; Division of Gastroenterology, Rambam Healthcare campus, Haifa, Israel; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Ghersin I; Division of Gastroenterology, Rambam Healthcare campus, Haifa, Israel; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Bendersky AG; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Internal Medicine 'D', Rabin Medical Center, Petah Tikva, Israel., Avni-Biron I; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Snir Y; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Banai H; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Broytman Y; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Perl L; Rabin Medical Center Innovation Lab, Rabin Medical Center, Petah Tikva, Israel., Dotan I; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Ollech JE; Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. Electronic address: kollech@gmail.com.
المصدر: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver [Dig Liver Dis] 2024 Jul 02. Date of Electronic Publication: 2024 Jul 02.
Publication Model: Ahead of Print
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 100958385 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3562 (Electronic) Linking ISSN: 15908658 NLM ISO Abbreviation: Dig Liver Dis Subsets: MEDLINE
أسماء مطبوعة: Publication: 2003- : Amsterdam : Elsevier
Original Publication: Roma, Italy : Editrice gastroenterologica italiana, c2000-
مستخلص: Objective: Drug sustainability (DS), a surrogate marker for drug efficacy, is important, especially when aiming for precision medicine. However, it lacks reliable prediction methods.
Aims: To develop and externally validate a web-based artificial intelligence(AI)-derived tool for predicting DS of infliximab and vedolizumab in patients with moderate-to-severe Ulcerative Colitis (UC).
Methods: Data from three Israeli centers included infliximab or vedolizumab patients treated for >54 weeks. Sustainability meant no corticosteroids, hospitalizations or surgeries. Machine learning techniques predicted >54-week and overall DS using baseline clinical data.
Results: The model was developed using data from 246 patients from Rabin Medical Center and externally validated on 67 patients from Rambam Health Care Campus and Sheba Medical Center. No significant difference in DS was observed across the datasets. Most patients were biologic-naïve and primarily treated with vedolizumab. The model performed well, with an area under the ROC curve of 0.86, and showed good accuracy (65.5 %-76.9 %) across the test sets.
Conclusions: The study introduces a novel, AI-based tool for predicting >54-week DS of infliximab and vedolizumab in moderate-to-severe UC, using baseline parameters. This can aid clinical decision-making in the framework of precision medicine, promising to optimize disease management while maintaining physician autonomy.
Competing Interests: Conflicts of interest HY- Has received research grants from Pfizer; consulting fees from Abbvie, Janssen, Pfizer, Takeda, and BMS; Speaker fees from Abbvie, Janssen, Pfizer, Takeda, and Bristol Myers Squibb; Data Safety Monitoring Board or Advisory Board fees from Abbvie, Pfizer Takeda and Bristol Myers Squibb. JEO- Has received grant support from Pfizer, consulting fees from Takeda, and speaker fees from Abbvie, Janssen, Pfizer, Takeda, Novartis, and Bristol Myers Squibb. IAB- Has received speaker fees from Abbvie, Janssen, Pfizer, Takeda, and Neopharm. ID- consultation fee or honorarium from: Abbott, Abbvie, Athos, Arena, Altman Research, Cambridge Healthcare, Celltrion, Celgene/BMS, Eli-Lilly, Ferring, Falk Pharma, Food Industries Organization, Gilead, Galapagos, Iterative Scopes, Integra Holdings, Janssen, Neopharm, Pfizer, Rafa laboratories, Roche/Genentech, Sangamo, Sublimity, Sandoz, Takeda, Wildbio. Grants: Altman Research, BMS, Pfizer UK- Research support- Jannsen, Takeda, Medtronic, speaker/advisory fees- Abbvie BMS Celtrion Jannsen Pfizer Takeda Medtronic Roche No specific funding has been received for this study.
(Copyright © 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.)
فهرسة مساهمة: Keywords: Artificial intelligence; Clinical decision making; Inflammatory bowel diseases; Machine learning
تواريخ الأحداث: Date Created: 20240703 Latest Revision: 20240703
رمز التحديث: 20240704
DOI: 10.1016/j.dld.2024.06.008
PMID: 38960819
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-3562
DOI:10.1016/j.dld.2024.06.008